TY - JOUR
T1 - Annual malignant transformation rate of oral leukoplakia remains consistent
T2 - A long-term follow-up study
AU - Evren, I.
AU - Brouns, E.R.
AU - Wils, L.J.
AU - Poell, J.B.
AU - Peeters, C.F.W.
AU - Brakenhoff, R.H.
AU - Bloemena, E.
AU - de Visscher, J.G.A.M.
N1 - Publisher Copyright: © 2020 Elsevier Ltd Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Objectives: Numerous clinical and histopathological characteristics have been associated with malignant transformation (MT) of oral leukoplakia (OL), including classic and differentiated epithelial dysplasia, but MT predictions remain suboptimal. The objective of this study was to determine the annual MT rate of OL and to identify clinicopathological risk factors associated with MT. Patients and methods: 170 patients with OL were included in this retrospective cohort study, 117 females and 53 males. Follow-up ranged from 12 to 219 months (median 54). The analyzed variables included age, gender, smoking habits, clinical presentation, subsite, size and treatment. In a subgroup of 140 patients, histopathological diagnoses were reviewed with regard to the presence of dysplasia, discerning both classic dysplasia and differentiated dysplasia. Results: MT occurred in 23% of the patients, resulting in an annual MT rate of 4.9% (95% CI: 3.5 – 6.6) which remained consistent. High-risk subsite (tongue and floor of mouth) was the only clinical predictor for MT (Hazard Ratio = 2.7, 95% CI: 1.3 – 5.5, p = 0.007). In 140 patients, classic dysplasia (Hazard Ratio = 7.2, 95% CI: 1.6 – 33.1, p = 0.012) and differentiated dysplasia (Hazard Ratio = 6.6, 95% CI: 1.2 – 25.4, p = 0.026) were predictors for MT. Binary grading between dysplasia and no dysplasia was significant for predicting MT (Hazard Ratio = 6.4, 95% CI: 1.5 – 27.5, p = 0.013). Conclusion: Since annual MT rate of OL remains stable during follow-up, regular long-term or even life-long follow-up is advocated. Specific oral subsites and epithelial dysplasia are predictors for MT of OL.
AB - Objectives: Numerous clinical and histopathological characteristics have been associated with malignant transformation (MT) of oral leukoplakia (OL), including classic and differentiated epithelial dysplasia, but MT predictions remain suboptimal. The objective of this study was to determine the annual MT rate of OL and to identify clinicopathological risk factors associated with MT. Patients and methods: 170 patients with OL were included in this retrospective cohort study, 117 females and 53 males. Follow-up ranged from 12 to 219 months (median 54). The analyzed variables included age, gender, smoking habits, clinical presentation, subsite, size and treatment. In a subgroup of 140 patients, histopathological diagnoses were reviewed with regard to the presence of dysplasia, discerning both classic dysplasia and differentiated dysplasia. Results: MT occurred in 23% of the patients, resulting in an annual MT rate of 4.9% (95% CI: 3.5 – 6.6) which remained consistent. High-risk subsite (tongue and floor of mouth) was the only clinical predictor for MT (Hazard Ratio = 2.7, 95% CI: 1.3 – 5.5, p = 0.007). In 140 patients, classic dysplasia (Hazard Ratio = 7.2, 95% CI: 1.6 – 33.1, p = 0.012) and differentiated dysplasia (Hazard Ratio = 6.6, 95% CI: 1.2 – 25.4, p = 0.026) were predictors for MT. Binary grading between dysplasia and no dysplasia was significant for predicting MT (Hazard Ratio = 6.4, 95% CI: 1.5 – 27.5, p = 0.013). Conclusion: Since annual MT rate of OL remains stable during follow-up, regular long-term or even life-long follow-up is advocated. Specific oral subsites and epithelial dysplasia are predictors for MT of OL.
KW - Annual malignant transformation rate
KW - Differentiated dysplasia
KW - Head and neck cancer
KW - Malignant transformation
KW - Oral cancer
KW - Oral dysplasia
KW - Oral leukoplakia
KW - Oral potentially malignant disorder
KW - Risk factors
KW - Risk prediction
UR - http://www.scopus.com/inward/record.url?scp=85092071735&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.oraloncology.2020.105014
DO - https://doi.org/10.1016/j.oraloncology.2020.105014
M3 - Article
C2 - 33038723
SN - 1368-8375
VL - 110
JO - Oral Oncology
JF - Oral Oncology
M1 - 105014
ER -